- Home
- ELLO vs OABI Comparison
ELLO vs OABI Comparison
Compare ELLO & OABI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELLO
- OABI
- Stock Information
- Founded
- ELLO 1987
- OABI 2012
- Country
- ELLO Israel
- OABI United States
- Employees
- ELLO N/A
- OABI N/A
- Industry
- ELLO Electric Utilities: Central
- OABI Biotechnology: Pharmaceutical Preparations
- Sector
- ELLO Utilities
- OABI Health Care
- Exchange
- ELLO Nasdaq
- OABI Nasdaq
- Market Cap
- ELLO 222.3M
- OABI 240.5M
- IPO Year
- ELLO 1995
- OABI N/A
- Fundamental
- Price
- ELLO $18.58
- OABI $1.61
- Analyst Decision
- ELLO
- OABI Strong Buy
- Analyst Count
- ELLO 0
- OABI 3
- Target Price
- ELLO N/A
- OABI $6.67
- AVG Volume (30 Days)
- ELLO 4.4K
- OABI 513.0K
- Earning Date
- ELLO 09-29-2025
- OABI 08-06-2025
- Dividend Yield
- ELLO N/A
- OABI N/A
- EPS Growth
- ELLO N/A
- OABI N/A
- EPS
- ELLO 0.43
- OABI N/A
- Revenue
- ELLO $44,405,534.00
- OABI $23,027,000.00
- Revenue This Year
- ELLO N/A
- OABI N/A
- Revenue Next Year
- ELLO N/A
- OABI $44.99
- P/E Ratio
- ELLO $46.38
- OABI N/A
- Revenue Growth
- ELLO N/A
- OABI 6.05
- 52 Week Low
- ELLO $11.30
- OABI $1.22
- 52 Week High
- ELLO $20.81
- OABI $4.87
- Technical
- Relative Strength Index (RSI)
- ELLO 62.47
- OABI 34.89
- Support Level
- ELLO $17.30
- OABI $1.55
- Resistance Level
- ELLO $17.55
- OABI $1.94
- Average True Range (ATR)
- ELLO 0.47
- OABI 0.11
- MACD
- ELLO 0.03
- OABI -0.04
- Stochastic Oscillator
- ELLO 78.43
- OABI 16.67
About ELLO Ellomay Capital Ltd (Israel)
Ellomay Capital Ltd is a renewable energy company. It develops and operates renewable energy projects in Europe, the USA, and Israel, employing diverse technologies such as solar power, natural gas, pumped hydro, and waste-to-energy solutions.
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. It focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.